Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors.
Colley CS, Popovic B, Sridharan S, Debreczeni JE, Hargeaves D, Fung M, An LL, Edwards B, Arnold J, England E, Eghobamien L, Sivars U, Flavell L, Renshaw J, Wickson K, Warrener P, Zha J, Bonnell J, Woods R, Wilkinson T, Dobson C, Vaughan TJ. Colley CS, et al. Among authors: england e. MAbs. 2018 Jan;10(1):104-117. doi: 10.1080/19420862.2017.1384892. Epub 2017 Oct 24. MAbs. 2018. PMID: 28952876 Free PMC article.
Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.
Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S, Rendall E, Sinha M, Walker C, Rees G, Bowen MA, Schneider A, Liang M, Faggioni R, Fung M, Mallinder PR, Wilkinson T, Kolbeck R, Vaughan T, Lowe DC. Finch DK, et al. Among authors: england e. J Mol Biol. 2011 Aug 26;411(4):791-807. doi: 10.1016/j.jmb.2011.06.031. Epub 2011 Jun 23. J Mol Biol. 2011. PMID: 21723291
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.
Cohen ES, Dobson CL, Käck H, Wang B, Sims DA, Lloyd CO, England E, Rees DG, Guo H, Karagiannis SN, O'Brien S, Persdotter S, Ekdahl H, Butler R, Keyes F, Oakley S, Carlsson M, Briend E, Wilkinson T, Anderson IK, Monk PD, von Wachenfeldt K, Eriksson PO, Gould HJ, Vaughan TJ, May RD. Cohen ES, et al. Among authors: england e. MAbs. 2014 May-Jun;6(3):756-64. doi: 10.4161/mabs.28394. Epub 2014 Feb 28. MAbs. 2014. PMID: 24583620 Free PMC article.
Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope "tags".
Percival-Alwyn JL, England E, Kemp B, Rapley L, Davis NH, McCarthy GR, Majithiya JB, Corkill DJ, Welsted S, Minton K, Cohen ES, Robinson MJ, Dobson C, Wilkinson TC, Vaughan TJ, Groves MA, Tigue NJ. Percival-Alwyn JL, et al. Among authors: england e. MAbs. 2015;7(1):129-37. doi: 10.4161/19420862.2014.985489. MAbs. 2015. PMID: 25523454 Free PMC article.
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation.
Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, Rees DG, Overed-Sayer CL, Woods J, Bond NJ, Veyssier CS, Embrey KJ, Sims DA, Snaith MR, Vousden KA, Strain MD, Chan DT, Carmen S, Huntington CE, Flavell L, Xu J, Popovic B, Brightling CE, Vaughan TJ, Butler R, Lowe DC, Higazi DR, Corkill DJ, May RD, Sleeman MA, Mustelin T. Cohen ES, et al. Among authors: england e. Nat Commun. 2015 Sep 14;6:8327. doi: 10.1038/ncomms9327. Nat Commun. 2015. PMID: 26365875 Free PMC article.
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.
England E, Rees DG, Scott IC, Carmen S, Chan DTY, Chaillan Huntington CE, Houslay KF, Erngren T, Penney M, Majithiya JB, Rapley L, Sims DA, Hollins C, Hinchy EC, Strain MD, Kemp BP, Corkill DJ, May RD, Vousden KA, Butler RJ, Mustelin T, Vaughan TJ, Lowe DC, Colley C, Cohen ES. England E, et al. Sci Rep. 2023 Jun 17;13(1):9825. doi: 10.1038/s41598-023-36642-y. Sci Rep. 2023. PMID: 37330528 Free PMC article.
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TI, Sansom DM, Bowen MA, Minter RR, Jermutus L. Douthwaite J, et al. Among authors: england e. J Immunol. 2017 Jan 1;198(1):528-537. doi: 10.4049/jimmunol.1600682. Epub 2016 Nov 23. J Immunol. 2017. PMID: 27881707
Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TIM, Sansom DM, Bowen MA, Minter RR, Jermutus L. Douthwaite J, et al. Among authors: england e. J Immunol. 2017 Sep 1;199(5):1943. doi: 10.4049/jimmunol.1790013. J Immunol. 2017. PMID: 28827388 No abstract available.
204 results